792 related articles for article (PubMed ID: 16989457)
1. [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].
Lisowska G; Namysłowski G; Hajduk A; Polok A; Tomaszewska R; Misiołek M
Otolaryngol Pol; 2006; 60(3):415-20. PubMed ID: 16989457
[TBL] [Abstract][Full Text] [Related]
2. [Hearing evaluation in children during chemotherapy].
Lisowska G; Namysłowski G; Hajduk A; Polok A; Tomaszewska R; Misiołek M
Pol Merkur Lekarski; 2005 Sep; 19(111):340-2. PubMed ID: 16358863
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
4. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
5. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
6. The effect of treatment with vincristine on transient evoked and distortion product otoacoustic emissions.
Riga M; Psarommatis I; Korres S; Lyra Ch; Papadeas E; Varvutsi M; Ferekidis E; Apostolopoulos N
Int J Pediatr Otorhinolaryngol; 2006 Jun; 70(6):1003-8. PubMed ID: 16359737
[TBL] [Abstract][Full Text] [Related]
7. Neurotoxicity of BFM-95 on the medial olivocochlear bundle assessed by means of contralateral suppression of 2f1-f2 distortion product otoacoustic emissions.
Riga M; Korres S; Psarommatis I; Varvutsi M; Giotakis I; Papadas T; Ferekidis E; Apostolopoulos N
Otol Neurotol; 2007 Feb; 28(2):208-12. PubMed ID: 17255889
[TBL] [Abstract][Full Text] [Related]
8. [Effect of inner ear hearing loss on delayed otoacoustic emissions (TEOAE) and distortion products (DPOAE)].
Hoth S
Laryngorhinootologie; 1996 Dec; 75(12):709-18. PubMed ID: 9081275
[TBL] [Abstract][Full Text] [Related]
9. Detection of hearing loss using 2f2-f1 and 2f1-f2 distortion-product otoacoustic emissions.
Fitzgerald TS; Prieve BA
J Speech Lang Hear Res; 2005 Oct; 48(5):1165-86. PubMed ID: 16411804
[TBL] [Abstract][Full Text] [Related]
10. Distortion-product otoacoustic emission: early detection in deferoxamine induced ototoxicity.
Delehaye E; Capobianco S; Bertetto IB; Meloni F
Auris Nasus Larynx; 2008 Jun; 35(2):198-202. PubMed ID: 17869044
[TBL] [Abstract][Full Text] [Related]
11. Distortion-product otoacoustic emission test performance for ototoxicity monitoring.
Reavis KM; McMillan G; Austin D; Gallun F; Fausti SA; Gordon JS; Helt WJ; Konrad-Martin D
Ear Hear; 2011 Feb; 32(1):61-74. PubMed ID: 20625302
[TBL] [Abstract][Full Text] [Related]
12. Test-retest reliability of distortion-product thresholds compared to behavioral auditory thresholds.
Bader K; Dierkes L; Braun LH; Gummer AW; Dalhoff E; Zelle D
Hear Res; 2021 Jul; 406():108232. PubMed ID: 33984603
[TBL] [Abstract][Full Text] [Related]
13. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.
Dille MF; McMillan GP; Reavis KM; Jacobs P; Fausti SA; Konrad-Martin D
J Acoust Soc Am; 2010 Sep; 128(3):1163-74. PubMed ID: 20815453
[TBL] [Abstract][Full Text] [Related]
14. Repeatability of high-frequency distortion-product otoacoustic emissions in normal-hearing adults.
Dreisbach LE; Long KM; Lees SE
Ear Hear; 2006 Oct; 27(5):466-79. PubMed ID: 16957498
[TBL] [Abstract][Full Text] [Related]
15. Changes in distortion product otoacoustic emissions from ears with Menière's disease.
Kusuki M; Sakashita T; Kubo T; Kyunai K; Ueno K; Hikawa C; Wada T; Nakai Y
Acta Otolaryngol Suppl; 1998; 538():78-89. PubMed ID: 9879406
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of cochlear function by means of otoacoustic emission in children treated with cytostatic drugs in the course of bone marrow proliferative diseases].
Namysłowski G; Trybalska G; Morawski K; Scierski W; Urbaniec P; Sońta-Jakimczyk D; Janik-Moszant A
Otolaryngol Pol; 2000; 54(6):769-74. PubMed ID: 11265390
[TBL] [Abstract][Full Text] [Related]
17. Patterns of change in growth function of distortion product otoacoustic emissions in Menière's disease.
Sakashita T; Kubo T; Kusuki M; Kyunai K; Ueno K; Hikawa C; Wada T; Shibata T; Nakai Y
Acta Otolaryngol Suppl; 1998; 538():70-7. PubMed ID: 9879405
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of glycerol test in Meniere's disease with pure tone audiometry and distortion product otoacoustic emission].
Jabłonka A; Pośpiech L; Orendorz-Fraczkowska K
Otolaryngol Pol; 2003; 57(5):731-7. PubMed ID: 14994621
[TBL] [Abstract][Full Text] [Related]
19. An investigation of hearing impairment in de-novo Parkinson's disease patients: A preliminary study.
Pisani V; Sisto R; Moleti A; Di Mauro R; Pisani A; Brusa L; Altavista MC; Stanzione P; Di Girolamo S
Parkinsonism Relat Disord; 2015 Aug; 21(8):987-91. PubMed ID: 26071125
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of distortion-product otoacoustic emissions in humans to tonal over-exposure: time course of recovery and effects of lowering L2.
Sutton LA; Lonsbury-Martin BL; Martin GK; Whitehead ML
Hear Res; 1994 May; 75(1-2):161-74. PubMed ID: 8071143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
